Kodiak Sciences Inc. KOD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-14.93
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$230.0M | — | -$136.5M | $157.4M |
| 2024 | — | -$176.2M | — | -$117.7M | $150.3M |
| 2023 | — | -$260.5M | — | -$195.5M | $265.8M |
| 2022 | — | -$333.8M | — | -$243.5M | $436.2M |
| 2021 | — | -$267.0M | — | -$199.3M | $663.3M |
| 2020 | — | -$133.1M | — | -$87.2M | $860.8M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -14.93 (distress)
- Working capital / assets 0.482
- Retained earnings / assets -4.434
- EBIT / assets -0.667
- Equity / liabilities 0.811
Source: SEC EDGAR filings · CIK 0001468748 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.